Liminatus Pharma, Inc.

Over the past 90 days, Liminatus Pharma (LIMNW) has recorded zero cyber incidents and zero red-flag 8-K filings related to bankruptcy, delisting, restatement, or officer departures. However, a quiet recent period does not eliminate structural risks; the absence of detected events in our short-term window reflects limited signal rather than comprehensive safety. The full $49 Report expands the analysis to 12 months of SEC filings, calculates dilution risk scores from financing history, identifies AI-flagged risk signals in executive changes and liquidity pressures, and contextualizes 8-K patterns within the company's capital structure. The full $49 Report adds historical depth, quantified dilution exposure, and forward-risk signals that a 90-day snapshot cannot capture.